Neumora's Phase 3 KOASTAL-1 study of navacaprant fails primary endpoint in MDD

Neumora Therapeutics, Inc.

Primary endpoint MADRS total score change at Week 6: -12.5 for both navacaprant and placebo (p=0.993); no statistical improvement.
Key secondary endpoint SHAPS also missed: -5.8 vs -5.5 (p=0.648).
Pre-specified subgroup analysis showed efficacy signal in females: MADRS LSMD -2.7 (p=0.072); SHAPS LSMD -2.3 (p=0.015).
Navacaprant generally well-tolerated; no serious adverse events; discontinuation 2.1% vs 3.1% for placebo.
Cash balance $342M provides runway into mid-2026; J.P. Morgan Healthcare Conference update planned Jan 14.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.